BeiGene, Ltd. (NASDAQ:BGNE) CFO Sells $67,920.80 in Stock

BeiGene, Ltd. (NASDAQ:BGNE) CFO Julia Aijun Wang sold 472 shares of the company’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $143.90, for a total value of $67,920.80. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Julia Aijun Wang also recently made the following trade(s):

• On Monday, June 24th, Julia Aijun Wang sold 899 shares of BeiGene stock. The shares were sold at an average price of $155.66, for a total value of $139,938.34.

BeiGene Stock Performance

BGNE opened at $147.04 on Friday. The company has a market cap of $14.19 billion, a PE ratio of -19.42 and a beta of 0.59. The stock has a 50-day moving average of $157.24 and a 200-day moving average of $158.59. BeiGene, Ltd. has a 52-week low of $126.97 and a 52-week high of $225.23. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.84 and a current ratio of 2.08.

BeiGene (NASDAQ:BGNE) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($2.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.07) by $0.66. The company had revenue of $751.70 million during the quarter, compared to the consensus estimate of $670.09 million. BeiGene had a negative return on equity of 21.70% and a negative net margin of 28.39%. The firm’s revenue was up 67.9% on a year-over-year basis. During the same quarter in the prior year, the company posted ($3.34) EPS. As a group, equities research analysts forecast that BeiGene, Ltd. will post -8.2 earnings per share for the current fiscal year.

Institutional Trading of BeiGene

Several large investors have recently made changes to their positions in BGNE. Capital International Investors boosted its stake in BeiGene by 11.5% during the 1st quarter. Capital International Investors now owns 7,064,428 shares of the company’s stock valued at $1,104,806,000 after purchasing an additional 727,556 shares during the period. First Trust Advisors LP bought a new stake in BeiGene during the 4th quarter valued at approximately $39,632,000. M&G Plc bought a new stake in BeiGene during the 1st quarter valued at approximately $29,649,000. Goldman Sachs Group Inc. boosted its stake in BeiGene by 175.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 214,339 shares of the company’s stock valued at $38,658,000 after purchasing an additional 136,458 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its stake in BeiGene by 6.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,026,094 shares of the company’s stock valued at $316,862,000 after purchasing an additional 117,905 shares during the period. Institutional investors own 48.55% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Sanford C. Bernstein dropped their price target on BeiGene from $196.00 to $161.00 and set a “market perform” rating on the stock in a research report on Wednesday, March 27th. TD Cowen upped their target price on BeiGene from $236.00 to $254.00 and gave the stock a “buy” rating in a research report on Thursday, May 9th. JPMorgan Chase & Co. upped their target price on BeiGene from $184.00 to $186.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 19th. Finally, Bank of America dropped their target price on BeiGene from $179.30 to $164.30 and set a “neutral” rating on the stock in a research report on Monday, April 8th. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $251.93.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.